Hyperphosphatemia is a nearly universal complication of end-stage renal disease that is
widely recognized as one of the most important and most challenging clinical targets to meet …

Cardiovascular (CV) disease (CVD) accounts for> 50% of deaths with known causes in
patients on dialysis. Elevated serum phosphorus levels are an important nontraditional risk …

Phosphate metabolism is crucial in the pathophysiology of secondary hyperparathyroidism
and vascular calcification. High phosphate levels have been consistently associated with …

Consequences of hyperphosphatemia in patients with end-stage renal disease (ESRD).
Hyperphosphatemia is invariably present among patients with end-stage renal disease …

Background: Cardiovascular disease (CVD) is a major cause of death in patients with
chronic kidney disease (CKD) on dialysis. Mortality rates are still unacceptably high even …

Optimal phosphate control in dialysis patients is extremely challenging. A growing
awareness of the deleterious effect of mineral metabolism imbalances together with the lack …

Hyperphosphataemia is prevalent among chronic renal failure and dialysis patients. It is
known to stimulate parathyroid hormone and suppress vitamin D3 production, thereby …

Hyperphosphatemia is a common complication in patients with chronic kidney disease
(CKD), particularly in those requiring renal replacement therapy. The importance of …

Hyperphosphatemia has consistently been shown to be associated with dismal outcome in a
wide variety of populations, particularly in chronic kidney disease (CKD). Compelling …

As renal function declines in patients with end-stage renal disease (ESRD), excess dietary
phosphorus accumulates in the bloodstream. Routine dialysis removes up to 70% of …